Bo Wan

Bo Wan

Auto-generated profile, based on publicly available information

Bo Wan

Centre for Stem Cells and Regenerative Medicine, King's College London, London, United Kingdom

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2021 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
XDXinyi Du-Harpur
Xinyi Du-Harpur
CACallum Arthurs
Callum Arthurs
CGClarisse Ganier
Clarisse Ganier
RWRick Woolf
Rick Woolf
ZLZainab Laftah
Zainab Laftah
MLMagnus D. Lynch
Magnus D. Lynch

29 May 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
CGClarisse Ganier
Clarisse Ganier
XDXinyi Du-Harpur
Xinyi Du-Harpur
NHNasrat Harun
Nasrat Harun
BWBo Wan
Bo Wan
CACallum Arthurs
Callum Arthurs
MLMagnus D. Lynch
Magnus D. Lynch
Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and is associated with a wide range of systemic manifestations. Several observations support a role for vascular endothelial dysfunction in the pathogenesis including an increased incidence of thrombotic events and coagulopathy and the presence of vascular risk factors as an independent predictor of poor prognosis. It has recently been reported that endothelitis is associated with viral inclusion bodies suggesting a direct role for SARS-CoV-2 in the pathogenesis. The ACE2 receptor has been shown to mediate SARS-CoV-2 uptake and it has been proposed that CD147 (BSG) can function as an alternative cell surface receptor. To define the endothelial cell populations that are susceptible to infection with SARS-CoV-2, we investigated the expression of ACE2 as well as other genes implicated in the cellular entry of SARS-Cov-2 in the vascular endothelium through the analysis of single cell sequencing data derived from multiple human tissues (skin, liver, kidney, lung and intestine). We found that CD147 ( BSG ) but not ACE2 is detectable in vascular endothelial cells within single cell sequencing datasets derived from multiple tissues in healthy individuals. This implies that either ACE2 is not expressed in healthy tissue but is instead induced in response to SARS-Cov2 or that SARS-Cov2 enters endothelial cells via an alternative receptor such as CD147.

1 January 2021 in BioMed Research International
Verified
Journal Article
Open access
PDF file
MMMeng Meng
Meng Meng
Chen BaiChen Bai
Chen Bai
BWBo Wan
Bo Wan
LZLuqing Zhao
Luqing Zhao
ZLZhe Li
Zhe Li
SZShengsheng Zhang
Shengsheng Zhang
Background and Objective. Irritable bowel syndrome (IBS) is a prevalent disorder of the gastrointestinal system with complex pathogenesis. Shenling Baizhu powder (SLBZP) is a Chinese herbal compound with multicomponent and multitarget characteristics. Increasing volumes of evidence demonstrate that it has a notable therapeutic impact on IBS. This study therefore is aimed at exploring the potential effective components of SLBZP and their mechanisms in IBS treatment utilizing network pharmacology. Methods. Metabolomics was used to detect the secondary metabolites in SLBZP; the target protein was acquired by target fishing according to the compound’s structure. The SymMap database was used to search herbal medicines for the target protein. The target gene of IBS gave rise to the common gene protein which is the potential target of SLBZP in IBS therapy. The interactions between target proteins were analyzed in a STRING database, the protein relationship network was analyzed using Cytoscape software, and the Kyoto Encyclopedia of Genes and Genomes enrichment analysis of the core target gene group was carried out in a DAVID database in order to construct the “compound‐traditional Chinese medicine/molecule‐target‐pathway” network. Molecular docking was used to verify the core protein and its related small molecular compounds. Result. There were 129 types of secondary metabolites in SLBZP. 80 target proteins of these metabolites were potential core targets for IBS treatment including acetylcholinesterase (AChE), arachidonate‐5‐lipoxygenase (ALOX5), B‐cell lymphoma‐2 (BCL2), recombinant cyclin D1 (CCND1), and catenin‐β1 (CTNNB1), among others. Results from these targets indicated that the most enriched pathway was the tumor necrosis factor (TNF) signaling pathway (p < 0.001) and that the most abundant pathway was signal transduction. In the network nodes of the TNF signaling pathway, the Chinese medicines with the highest aggregation were Lablab semen album and Glycyrrhizae radix et rhizoma (degree = 11). The small molecules with the highest aggregation were oxypeucedanin and 3,5,6,7,8,3 ′,4 ′‐heptamethoxyflavone (degree = 4). Molecular docking results confirmed that daidzein 7‐O‐glucoside (daidzin) had the highest degree of binding to TNF proteins in the TNF signaling pathway. Conclusion. This study shows that SLBZP can treat IBS by influencing multiple targets and pathways, of which the TNF signaling pathway may be the most significant. This typifies the pharmacological characteristics of traditional Chinese medicine, i.e., multiple targets, numerous pathways, and specific therapeutic effects on diseases. SLBZP can therefore be used as a candidate drug for clinical IBS by intervening in human signal transduction.